Suppr超能文献

慢性非癌症呼吸系统疾病所致呼吸困难的阿片类药物处方方法:系统评价。

Opioid Prescription Method for Breathlessness Due to Non-Cancer Chronic Respiratory Diseases: A Systematic Review.

机构信息

Department of Pulmonary Medicine, Jichi Medical University Saitama Medical Center, Saitama 330-8503, Japan.

Department of Public Health and Health Systems, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.

出版信息

Int J Environ Res Public Health. 2022 Apr 18;19(8):4907. doi: 10.3390/ijerph19084907.

Abstract

A previous pooled analysis demonstrated significant relief of breathlessness following opioid administration in patients with chronic obstructive pulmonary disease. However, in clinical practice, it is important to know the characteristics of patients responding to opioids, the best prescription methods, and the evaluation measures that can sufficiently reflect these effects. Thus, we performed a systematic review of systemic opioids for non-cancer chronic respiratory diseases. Fifteen randomized controlled studies (RCTs), four non-randomized studies, two observational studies, and five retrospective studies were included. Recent RCTs suggested that regular oral opioid use would decrease the worst breathlessness in patients with a modified Medical Research Council score ≥ 3 by a degree of 1.0 or less on a scale of 1-10. Ergometer or treadmill tests indicated mostly consistent significant acute effects of morphine or codeine. In two non-randomized studies, about 60% of patients responded to opioids and showed definite improvement in symptoms and quality of life. Furthermore, titration of opioids in these studies suggested that a major proportion of these responders had benefits after administration of approximately 10 mg/day of morphine. However, more studies are needed to clarify the prescription method to reduce withdrawal due to adverse effects, which would lead to significant improvements in overall well-being.

摘要

先前的一项汇总分析表明,在慢性阻塞性肺疾病患者中,阿片类药物给药后呼吸困难明显缓解。然而,在临床实践中,了解对阿片类药物有反应的患者的特征、最佳处方方法以及能够充分反映这些效果的评估措施非常重要。因此,我们对非癌症慢性呼吸系统疾病的全身性阿片类药物进行了系统评价。共纳入 15 项随机对照研究(RCT)、4 项非随机研究、2 项观察性研究和 5 项回顾性研究。最近的 RCT 表明,定期口服阿片类药物可使改良的医学研究委员会评分≥3 的患者的最严重呼吸困难程度降低 1.0 或更低,评分为 1-10。测力计或跑步机测试表明,吗啡或可待因的急性作用大多一致显著。在两项非随机研究中,约 60%的患者对阿片类药物有反应,并表现出症状和生活质量的明显改善。此外,这些研究中的阿片类药物滴定表明,在这些有反应者中,很大一部分人在每天约 10 毫克吗啡给药后获益。然而,仍需要更多的研究来阐明处方方法,以减少因不良反应而导致的停药,这将显著改善整体健康状况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13dd/9024433/e1aa5da1066f/ijerph-19-04907-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验